6-溴-N,N-二甲基吡啶-2-胺 | 112575-13-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 6-溴-N,N-二甲基吡啶-2-胺
• 英文名称: 6-bromo-N,N-dimethylpyridin-2-amine
• CAS: 112575-13-0
• 化学式: C₇H₉BrN₂
• 分子量: 201.066
• InChiKey: MIOQBSPUPLFYHC-UHFFFAOYSA-N

物化性质

• 熔点：
  56-57 °C(Solv: cyclohexane (110-82-7))
• 沸点：
  282.0±20.0 °C(Predicted)
• 密度：
  1.469±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-2-N,N-dimethylaminopyridine
Synonyms: 6-Bromo-N,N-dimethylpyridin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-2-N,N-dimethylaminopyridine
CAS number: 112575-13-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H9BrN2
Molecular weight: 201.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-N,N-二甲基吡啶-2-胺 在 正丁基锂 、 硼酸三异丙酯 、 二氟化氢钾 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 4.0h， 以32%的产率得到potassium 6-N,N-dimethylpyridine-2-trifluoroborate
  参考文献：
  名称：

  钯催化的2-吡啶基三氟硼酸钾与芳基（杂芳基）卤化物的铃木-宫浦交叉偶联反应

  摘要：

  吡啶-2-三氟硼酸钾与各种芳基（杂芳基）卤化物的钯催化的Suzuki-Miyaura交叉偶联反应可以产生相应的所需偶联产物，产率中等至良好。可以在以下条件下进行：乙醇为溶剂，Pd（OAc）2和SPhos为催化剂体系，Na 2 CO 3为碱。

  DOI：

  10.1016/j.tet.2011.12.036
• 作为产物：
  描述：

  2,6-二溴吡啶 、 二甲胺 以 四氢呋喃 为溶剂， 以93 %的产率得到6-溴-N,N-二甲基吡啶-2-胺
  参考文献：
  名称：

  锰催化环酮对映选择性氢化的面配位 P,N,N 配体的合理设计

  摘要：

  Mn催化剂经过合理的重新设计，可以排斥sp 3杂化取代基，同时吸引sp 2取代基，从而实现环酮的对映选择性氢化。 DFT 计算能够对一系列底物的对映控制水平进行可靠预测。

  DOI：

  10.1002/anie.202212479

文献信息

• [EN] BENZOSULFONYL COMPOUNDS<br/>[FR] COMPOSÉS DE BENZOSULFONYLE
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2019040380A1

  公开（公告）日：2019-02-28

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

  本文提供了包含所述化合物的用于治疗癌症的药物组合物。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。
• Amination of Aromatic Halides and Exploration of the Reactivity Sequence of Aromatic Halides
  作者：Chu Yang、Feng Zhang、Guo-Jun Deng、Hang Gong

  DOI：10.1021/acs.joc.8b02588

  日期：2019.1.4

  A base-promoted amination of aromatic halides has been developed using a limited amount of dimethylformamide (DMF) or amine as an amino source. Various aryl halides, including F, Cl, Br, and I, have been successfully aminated in good to excellent yields. Although the amination of aromatic halides with amines or DMF is usually considered as an aromatic nucleophilic substitution (SNAr) process, and the

  使用有限量的二甲基甲酰胺（DMF）或胺作为氨基源，已经开发出碱促进的芳香族卤化物胺化。包括F，Cl，Br和I在内的各种芳基卤化物均已成功地以良好或优异的收率胺化。尽管通常将胺或DMF芳香卤化物胺化视为芳香亲核取代（S NAr）过程，芳族卤化物的反应性为F> Cl> Br> I，发现该体系中芳族卤化物的反应性为I> Br≈F> Cl。该方案还显示了对多卤代芳烃的良好区域选择性。由于操作简单，氨基源和芳族卤化物的不受限制的可用性，无过渡金属的条件，不需要溶剂以及可扩展性，该协议对于工业应用很有价值。
• Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors
  作者：Scott H. Henderson、Fiona Sorrell、James Bennett、Oleg Fedorov、Marcus T. Hanley、Paulo H. Godoi、Roberta Ruela de Sousa、Sean Robinson、Alexander Ashall-Kelly、Iva Hopkins Navratilova、Daryl S. Walter、Jonathan M. Elkins、Simon E. Ward

  DOI：10.1021/acs.jmedchem.1c01115

  日期：2021.8.12

  pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the

  双特异性酪氨酸调节激酶​​ 1A (DYRK1A) 调节大脑发育过程中神经元祖细胞的增殖和分化。因此，DYRK1A 作为治疗神经退行性疾病（包括阿尔茨海默病（AD）和唐氏综合症）的靶标引起了人们的兴趣。最近，DYRK1A 的抑制已被研究为糖尿病的潜在治疗方法，而 DYRK1A 作为细胞周期介质的作用引起了人们对肿瘤适应症的兴趣。构效关系（SAR）分析与高分辨率X射线晶体学相结合，产生了一系列吡唑并[1,5- b ]哒嗪抑制剂，具有优异的配体效率、良好的理化性质以及对其他药物的高度选择性。激酶。化合物11表现出良好的渗透性和细胞活性，且无需 P-糖蛋白，从而扩展了11在体内环境中的效用。这些吡唑并[1,5- b ]哒嗪是发现治疗与 DYRK1A 功能相关疾病的新疗法的可行的先导系列。
• Ligand-controlled, Pd/CuH-catalyzed reductive cross-coupling of terminal alkenes and <i>N</i>-heteroaryl bromides
  作者：Sanghyup Seo、Donghyeon Kim、Hyunwoo Kim

  DOI：10.1039/d1cc04833c

  日期：——

  The reductive cross-coupling of terminal alkenes and N-heterocyclic bromides has been demonstrated by ligand optimization of Pd and CuH catalysis. The optimized ligands are Briphos, a π-acceptor monodentate phosphorus ligand, for Pd catalysis and DTB-DPPBz, a sterically bulky bidentate phosphorus ligand, for CuH catalysis. These conditions were further applied to the gram-scale production of clathryimine

  通过 Pd 和 CuH 催化的配体优化已经证明了末端烯烃和 N-杂环溴化物的还原性交叉偶联。优化的配体是 Briphos，一种 π 受体单齿磷配体，用于 Pd 催化和 DTB-DPPBz，一种空间庞大的双齿磷配体，用于 CuH 催化。这些条件进一步应用于克级规模生产网格亚胺 B。
• Development of an ¹⁸F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues
  作者：Robert Wodtke、Johanna Wodtke、Sandra Hauser、Markus Laube、David Bauer、Rebecca Rothe、Christin Neuber、Markus Pietsch、Klaus Kopka、Jens Pietzsch、Reik Löser

  DOI：10.1021/acs.jmedchem.1c00096

  日期：2021.3.25

  activity of transglutaminase 2 (TGase 2) is considered to be important for several pathophysiological processes including fibrotic and neoplastic tissue growth, whereas in healthy cells this enzymatic function is predominantly latent. Methods that enable the highly sensitive detection of TGase 2, such as application of radiolabeled activity-based probes, will support the exploration of the enzyme’s function

  转谷氨酰胺酶2（TGase 2）的转酰胺酶活性被认为对包括纤维化和赘生性组织生长在内的几种病理生理过程很重要，而在健康细胞中，这种酶功能主要是潜伏的。能够高度敏感地检测TGase 2的方法，例如基于放射性标记的基于活性的探针的应用，将支持对该酶在各种疾病中的功能的探索。在这种情况下，放射合成和详述体外一个的radiopharmacological评价18 F-标记Ñ ε报道了丙烯酰赖氨酸哌嗪。对于分离的蛋白质，细胞裂解物和活细胞，由于不可逆的共价键形成，在色谱和电泳分离后，通过薄层板和聚丙烯酰胺凝胶的放射自显影对放射性示踪剂-TGase 2复合物进行了稳健而简便的检测。通过使用这种放射性示踪剂，首次通过组织切片的放射自显影获得了可激活的TGase 2在小鼠器官和选定的肿瘤中的表达谱的定量数据。